摘要
目的探究子痫前期患者血清载脂蛋白E(ApoE)联合脂蛋白相关磷脂酶A2(Lp-PLA2)水平对病情严重程度的评估价值。方法收集2020年1月至2022年10月安徽理工大学第一附属医院收治的101例子痫前期患者的临床资料,根据疾病严重程度分为轻度组及重度组。检测患者血清ApoE及Lp-PLA2水平;子痫前期病情严重程度的影响因素采用logistic回归分析;受试者操作特征曲线分析血清ApoE联合Lp-PLA2水平对子痫前期病情严重程度的评估价值。结果101例子痫前期患者中病情轻度78例,重度23例。重度组高血压病史人数占比,血清ApoE、Lp-PLA2水平高于轻度组(P<0.05)。血清ApoE、Lp-PLA2水平是子痫前期病情严重程度的独立危险因素(OR=3.282、2.772,P<0.05)。血清ApoE联合Lp-PLA2评估子痫前期病情严重程度的曲线下面积高于各指标单独检测。结论子痫前期患者血清ApoE、Lp-PLA2水平与病情严重程度有关,二者联合诊断价值高。
Objective To explore the value of serum apolipoprotein E(ApoE)combined with lipoprotein-associated phospholipase A2(Lp-PLA2)levels in evaluating the severity of preeclampsia.Methods The clinical data of 101 cases of preeclampsia patients admitted to the First Affiliated Hospital of Anhui University of Science and Technology from January 2020 to October 2022 were collected.They were divided into mild group and severe group according to the severity of the disease.The serum ApoE and Lp-PLA2 levels of patients were detected;the factors affecting the severity of the preeclampsia patients were analyzed by logistic regression;the value of serum ApoE combined with Lp-PLA2 levels in evaluating the severity of preeclampsia was analyzed by receiver operating characteristic curve.Results Among the 101 cases of preeclampsia,78 cases were mild,23 cases were severe.The proportion of hypertension,serum ApoE and Lp-PLA2 levels in severe group were higher than those in mild group(P<0.05).Serum ApoE and Lp-PLA2 levels were independent risk factors for the severity of preeclampsia(OR=3.282,2.772,P<0.05).The area under the curve of serum ApoE combined with Lp-PLA2 to assess the severity of preeclampsia was higher than that detected by each indicator alone.Conclusion Serum ApoE and Lp-PLA2 levels in patients with preeclampsia are related to the severity of the disease,and their combined diagnosis value is high.
作者
吴泉
程锦
WU Quan;CHENG Jin(Department of Obstetrics and Gynecology,the First Affiliated Hospital of Anhui University of Science and TechnologyHuainan First People’s Hospital,Anhui Province,Huainan 232000,China)
出处
《中国医药导报》
CAS
2023年第32期108-111,共4页
China Medical Herald
基金
安徽省高等学校科学研究项目(2022AH050803)。
